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Abstract 
Stanozolol (STZ) is a drug used to treat serious disorders like aplastic anemia and hereditary 
angioedema. It is also indicated as an adjunct therapy for the treatment of vascular disorders and 
growth failures. Encouraging results obtained using animal models demonstrated that STZ increases 
bone formation and mineralization, thus improving both density and biomechanical properties. Like 
natural androgens, such as TST and 5α-dihydrotestosterone (5α-DHT), STZ binds androgen receptor 
(AR) to activate AR-mediated signalling. Despite its therapeutic effects, this synthetic anabolic-
androgenic steroid (AAS), or 5α-DHT derivative, due to its high lipophilicity, is poor soluble in water. 
Thus, to increase the water solubility and stability of STZ, as well as its bioavailability and efficacy, 
an innovative PEGylated STZ (STZ conjugated with (MeO-PEG-NH2)10kDa, (MeO-PEG-NH)10kDa-
STZ) was synthesized. As confirmed by chromatography (RP-HPLC) and spectrometry (ATR-FTIR, 
1H-NMR, elemental CHNS(O) analysis, MALDI-TOF/TOF) analyses, a very pure, stable and soluble 
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compound was obtained. Acetylcholinesterase (AChE) competitive ELISA kit demonstrated that the 
resulting PEGylated STZ competes against biological TST, especially at lower concentrations. 
Cytotoxicity of increasing concentrations (1, 10, 25 or 50 µM) of STZ and/or (MeO-PEG-NH)10kDa-
STZ was also evaluated for up 80 h by performing the MTT assay on human osteosarcoma Saos-2 
cells, which express AR and are responsive to STZ. PEGylation mitigated cytotoxicity of STZ, by 
increasing the cell viability values, especially at higher drug concentrations. Furthermore, these 
results suggest that (MeO-PEG-NH)10kDa-STZ is a promising and reliable drug to be used in clinical 
conditions in which TST is required. 
 
1. Introduction 
Testosterone (TST) is the predominant androgen, which plays a key role in the growth of the primary 
male reproductive tissues and organs. This hormone is involved in every step of male sexual response, 
facilitating the development and maintenance of male secondary sexual traits as well as important 
functions like spermatogenesis. TST not only affects the male reproductive system, but it is also an 
essential hormone for women, with physiological actions mediated directly or via aromatisation of 
oestradiol throughout the body (Miah et al., 2019; Rastrelli et al., 2019; Shin et al., 2019). TST 
influences muscle mass, bone mineral density (BMD), erythropoiesis, and the activity of many other 
systems, by including the nervous system, where it plays a significant role in the regulation of mood 
and cognition (Bienenfeld et al., 2018; Rastrelli et al., 2018; Davis and Wahlin-Jacobsen, 2015). 
5α-dihydrotestosterone (5α-DHT) is a biologically active metabolite of the TST hormone. Stanozolol 
(STZ), or 17α-methyl-2'H-androst-2-eno[3,2-c]pyrazol-17β-ol, is a synthetic derivative of 5α-DHT 
formed by the condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Even 
though this synthetic anabolic-androgenic steroid (AAS) has binding affinity for the androgen 
receptor (AR) lower than that of the natural androgen TST, it strongly activates AR-mediated 
signalling (Feldkoren, and Andersson, 2005). Structural changes have been made to the TST 
molecule in order to maximize the anabolic effects and minimize the androgenic ones. Thus, from all 
compounds belonging to 17 α-alkylated AASs, STZ originates from the substitution of the 17 α-
hydrogen on the steroid nucleus for a methyl group. In addition, a pyrazole ring is attached to the A 
ring of the same steroid nucleus. Alkylation prevents its deactivation by hepatic first-pass metabolism 
(necessitating hepatic monitoring), which promotes oral activity. Therapeutic uses of STZ include the 
treatment of aplastic anemia and hereditary angioedema. It has also been indicated as an adjunct 
therapy for the treatment of vascular disorders and growth failures, which arise as a result of other 
medical conditions (National Center for Biotechnology Information, PubChem Database, 2019). 
Systemic administration of AASs is providing some encouraging results. Animal models treated with 
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AASs show an overall increase in bone formation and mineralization, as well as improvements in 
bone density and biomechanical properties (Guimarães et al., 2017; Donner et al., 2016; Liao et 
al., 2003). Intra-articular STZ administration induces positive effects on the synovial membrane and 
cartilage regeneration in osteoarthritis conditions (Spadari et al., 2013), and STZ-soaked 
deproteinized bone grafts increase new bone formation in calvarial critical-size defects (Ghiacci et 
al., 2017). Recently, Ghiacci et al. (2018) demonstrated that STZ promotes the osteogenic 
commitment of Saos-2 cells, by enhancing the mineralization process and modulating the expression 
of genes related to osteogenic differentiation (Ghiacci et al., 2018). However, STZ has a half-life of 
24 h and daily doses of it are necessary in order to maintain appropriate blood levels. Since STZ 
resembles to 5α-DHT molecule, therefore it cannot be aromatized to oestrogen. In addition, STZ also 
has a low water and salt retention (El Osta et al., 2016). The poor water solubility of STZ decreases 
its bioavailability, resulting in low efficacy, high inter-individual variability and, consequently, an 
unpredictable response (Lemma et al., 2017; Fasinu et al., 2011). To address these issues, herein, 
an innovative compound consisting of STZ conjugated with α-methoxy-ω-amino PEG having a 
nominal molecular weight (MW) of 10000 Da [(MeO-PEG-NH2)10kDa], (MeO-PEG-NH)10kDa-STZ, 
was synthesized. PEGylation using high MW PEGs (≥ 10 kDa) is an important strategy used to 
increase half-life, reduce renal clearance, and potentially decrease both the immunogenicity and 
cytotoxicity of therapeutics (Razzazan et al., 2016; Webster et al., 2009; Harris and Chess, 2003). 
The evaluation by Joint FAO/WHO Expert Committee on Food Additives (JECFA) included PEGs 
200, 300, 400, 600, 1000, 1500, 1540, 4000, 6000, 9000 and 10000. JECFA concluded that the acute 
and short-term studies cover a wide range of animal species and that PEGs have essentially similar 
toxicity, with toxicity being inverse to their MW (JECFA, 1980). These are the reasons why we 
chose such (MeO-PEG-NH2)10kDa. As shown in Scheme 1, a STZ molecule, after carbonate activation 
of its hydroxyl group by 4-nitrophenyl chloroformate, was conjugated to free primary amine group 
of (MeO-PEG-NH2)10kDa to form the (MeO-PEG-NH)10kDa-STZ conjugate (Product 2). Reverse phase 
high performance liquid chromatography (RP-HPLC), attenuated total reflectance-Fourier transform 
infrared (ATR-FTIR) and proton nuclear magnetic resonance (1H-NMR) spectroscopy, elemental 
carbon, hydrogen, nitrogen, sulfur and oxygen (CHNS(O)) analysis, matrix-assisted laser 
desorption/ionization time-of-flight/time-of-flight mass spectrometry (MALDI-TOF/TOF MS), 
enzyme-linked immunosorbent assay (ELISA) analyses and cytotoxic assessment (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT, assay) on human osteosarcoma Saos-
2 cells were performed in order to characterize and validate the successful synthesis of a biologically 
active (MeO-PEG-NH)10kDa-STZ conjugate (see Section 2.). 
2. Material and Methods 
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2.1. Material 
The α-methoxy-ω-amino polyethylene glycol with nominal molecular weight (MW) of 10,000 Da, 
(MeO-PEG-NH2)10kDa, was purchased from Iris Biotech GmbH (Marktredwitz, Germany; Product 
code: PEG1151). Human osteosarcoma Saos-2 cells (ATCC® HTB-85™) and McCoy’s 5A medium 
(ATCC® 30-2007™) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum 
(FBS), trypsin-EDTA (1×) and penicillin-streptomycin solutions were obtained from GIBCO 
(Thermo Fisher Scientific, Waltham, MA, USA). Chemicals were of analytical grade and provided 
by Sigma-Aldrich, unless otherwise indicated.  
 
2.2. Methods 
2.2.1. Synthesis of stanozolol-4-nitrophenyl-carbonate (Product 1) 
To activate Stanozolol (STZ, MW 328.49158 Da), 15 mg of STZ (22.83 mM) and 18.40 mg (45.64 
mM) of 4-nitrophenyl chloroformate (MW 201.56396 Da) were dissolved in 2 mL of anhydrous 
dichloromethane. The reaction was stirred at room temperature (RT) for 3 h in anhydrous condition. 
The activated STZ (yield 18.6 mg, 76.85%; degree of activation, as calculated from alkaline 
hydrolysis of fenate ion in NaOH 0.2 N, 95.5%) was filtered through celite, qualitatively analyzed 
using thin-layer chromatography (TLC), and purified by a silica gel (SiO2) column (4×12.5 cm) and 
a chloroform/methanol/mQ water mixture (78.5%: 19.5%: 2%, v/v) as eluent (Retention factor = 0.5). 
 
2.2.2. Synthesis of STZ conjugated with (MeO-PEG-NH2)10kDa, (MeO-PEG-NH)10kDa-STZ (Product 
2) 
451.9 mg (12.55 mM) of (MeO-PEG-NH2)10kDa and 10 mg (5.63 mM) of Product 1 (MW 493.5946) 
were dissolved in 3.6 mL of CH3CN/H2O (96.66%: 3.33% v/v), pH 8.0 (triethylamine). The reaction 
was let to proceed for 3 h under continuous stirring. pH was adjusted at 4.5 with 0.2 N HCl, then 
Product 2 was purified from the excess of 4-nitrophenyl chloroformate and unreacted STZ by 
extractions with diethyl ether (6×40 mL). The aqueous phase, containing Product 2 and the excess of 
(MeO-PEG-NH2)10kDa was dried under vacuum, solubilized in 2 mL of CHCl3 and separate on 
preparative TLC (yield 121 mg, 46%). The absence of free amine in the conjugate was verified 
spectrophotometrically (Cary® 50 UV-Vis spectrophotometer, Varian, Palo Alto, CA, USA) at 420 
nm after 30 min. of reaction by 2,4,6-trinitrobenzenesulfonic acid solution (TNBS) assay, according 
to Snyder and Sobocinski method (Snyder and Sobocinski, 1975). 
STZ: 1H-NMR (400 MHz, DMSO-d6) δppm 12.19 (s, 1H, –NH–), 7.22 (s, 1H, C19), 3.00-4.00 (m, (O–
CH2CH2)O–), 2.50 (m, 2H, C3), 2.09 (m, 2H, C6), 1.36 (m, 12H, C4,7,8,11,13-16), 1.08 (s, 3H, C22), 
0.84 (m, 2H, C9,10), 0.76 (s, 3H, C24), 0.67 (s, 3H, C23). 
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(MeO-PEG-NH2)10kDa: 1H-NMR (400 MHz, DMSO-d6) δppm 3.00-4.00 (m, (O–CH2CH2)O–). 
(MeO-PEG-NH)10kDa-STZ: 1H-NMR (400 MHz, DMSO-d6) δppm 7.72 (s, 1H, C19), 5.574 (s, 1H, –
NHCO–), 3.00-4.00 (m, (O–CH2CH2)O–), 2.50 (m, 2H, C3), 1.35 (m, 12H, C4,7,8,11,13-16), 0.84 (m, 
2H, C9,10), 0.76 (s, 3H, C24), 0.67 (s, 3H, C23). 
 
2.2.3. Evaluation of stability and solubility of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-
STZ stability 
STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ conjugate (1 mg/mL) were incubated at 
37 °C for up 80 h in phosphate buffer (PB) buffered at pH 5.8 and 7.4. Sink condition was maintained 
during the incubation time. Samples of 100 μL were withdrawn at predetermined times. STZ and 
(MeO-PEG-NH)10kDa-STZ samples were filtered by using Anotop® 10 LC syringe filter (alumina-
based membrane), pore size 0.2 μm (Whatman, Maidstone, UK) and analyzed by RP-HPLC by using 
a Waters Corp instrument equipped with binary pump and PDA detector, Phenomenex C18 column 
(Jupiter, 4.6×250 mm; 5 μm), with the UV detector settled at 230 nm. The eluents A and B were H2O 
and CH3OH, plus 0.05% (v/v) of trifluoroacetic acid (TFA) respectively. The elution was performed 
by the following gradient: from 5% B to 50% B in 5 min., from 50% B to 100% B in 30 min., plateau 
of B 100% B for 5 min., and from 100% B to 5% B in 5 min. at a flow rate of 0.8 mL/min. To test 
the stability of samples, the experiment was carried at 37 °C (selected temperature); in fact, PEG 
aggregates dispersed in water can form hydrophobic helical structures in the range of temperature 
from 35 to 40 °C as previously reported (Azri et al., 2012; Polik and Burchard, 1983). In addition, 
different classes of compounds are highly reactive toward the terminal amino group of the PEG 
(Akiyama et al., 2000). These processes lead to make less available and/or to replace this amino 
group with other functional groups, respectively. Thus, the time-dependent stability of (MeO-PEG-
NH2)10kDa was evaluated indirectly by assessing its free amino group, according to Snyder and 
Sobocinski method (Snyder and Sobocinski, 1975). Briefly, the high chromogenic product 
generated by the reaction of free amino group of (MeO-PEG-NH2)10kDa with TNBS was assessed 
spectrophotometrically (Cary® 50 UV-Vis spectrophotometer, Varian, Palo Alto, CA, USA) at 420 
nm after 30 min. of reaction. 
The solubility of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ conjugate was 
determined by dissolution in mQ water (25 °C, 1 atm). Briefly, 10 mL of mQ water was added to 10 
g of compound, then the mixture was filtered by using Anotop® 10 LC syringe filter (alumina-based 
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2.2.4. Attenuated total reflectance-Fourier transform infraRed (ATR-FTIR) spectroscopy 
ATR-FTIR was performed by using a Bruker VERTEX 70 series FTIR spectrometer (Bruker Optik 
GmbH, Ettlingen, Germany) and an ATR sampling accessory (MIRacle, Pike Technology Inc., Iselin, 
NJ; USA). The ATR-FTIR spectra were recorded in the wavenumber region of 4000-625 cm-1 with 
a spectral resolution of 4 cm-1 at RT, using OPUS 5.5 software (Bruker Optik GmbH, Ettlingen, 
Germany). 
 
2.2.5. Proton nuclear magnetic resonance (1H-NMR) spectroscopy 
1H-NMR spectra were acquired on a Bruker Ascend 400 MHz-Avance III HD NMR spectrometer 
(Bruker Corporation, Billerica, MA, USA) as solutions in deuterated dimethyl sulfoxide (DMSO-d6). 
Chemical shifts (δ) for 1H-NMR spectra are reported in parts per million (ppm) relative to the solvent 
residual peak at 2.50 ppm. Multiplicities of peaks are represented by s (singlet) and m (multiplet). All 
spectra were processed for recorded FID files with MestReNova 12.0.1 software (Mestrelab 
Research, Santiago de Compostela, Spain). 
 
2.2.6. Calculation of empirical formulas of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ 
by elemental CHNS(O) analysis 
The percentages of C, H, N, and S were recorded on dried samples of STZ, (MeO-PEG-NH2)10kDa 
and (MeO-PEG-NH)10kDa-STZ by using a vario MICRO cube CHNS analyzer (Elementar 
Analysensysteme GmbH, Langenselbold, Germany). The percentage of O was calculated by 
subtracting the percentages of C, H, N, and S from 100%. Sulphanilamide, the manufacturer 
recommended calibration standard, was run daily, prior to sample analysis and interspersed between 
samples, to compute the daily factor, the variation between the daily instrument response relative to 
the factory calibration, in order to apply the appropriate calibration factor (16.25% N, 41.81% C, 
18.62% S, 4.65% H). The daily factor was also run to calculate the systematic error for analysis. 
Integration limits set are reported in Table 1. The integration limits represent the peak area of each 
element obtained from the elemental analysis. Empirical formulas were calculated based on the 
percentage of each element and the respective theoretical empirical formulas of STZ (C21H32N2O), 
(MeO-PEG-NH2)10kDa (C5H13NO2∙[C2H4O]225) and (MeO-PEG-NH)10kDa-STZ 
(C27H43N3O4∙[C2H4O]225). If integrated areas were under integration limits, the elements were under 
the limit of quantification (LOQ). 
2.2.7. Matrix-assisted laser desorption/ionization time-of-flight/time-of-flight mass spectrometry 
(MALDI-TOF/TOF MS) 
 
- 7 - 
 
(MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ were analyzed by Ultraflex MALDI TOF/TOF 
instrument (Bruker Daltonics GmbH, Bremen, Germany) equipped with a nitrogen laser operating at 
337 nm. The mass spectra were acquired in positive ion linear and/or reflector mode using ultrapure 
Sinapic acid (Sigma-Aldrich, USA) as the matrix and external calibration with Protein calibration 
standard I (Bruker part # 206355). 
(MeO-PEG-NH2)10kDa: m/z 5065.0, Intens. 129.00; 5122.5, 129.00; 5174.2, 132.00; 5228.3, 146.00; 
5244.7, 143.00; 5344.2, 148.00; 5354.9, 131.00; 5371.9, 133.00; 5398.0, 152.00; 5439.6, 156.00; 
5463.2, 154.00; 5487.2, 141.00; 5494.0, 157.00; 5514.1, 155.00; 5526.3, 133.00; 5536.0, 153.00; 
5553.0, 151.00; 5581.2, 139.00; 5589.8, 166.00; 5602.9, 154.00; 5613.8, 135.00; 5625.9, 137.00; 
5667.1, 131.00; 5669.3, 129.00; 5694.5, 150.00; 5711.8, 147.00; 5751.4, 141.00; 5817.6, 138.00; 
5842.1, 135.00; 5904.9, 138.00; 5922.8, 151.00; 5950.8, 148.00; 5968.9, 169.00; 5986.3, 142.00; 
5999.6, 153.00; 6068.0, 134.00; 6152.9, 138.00; 6216.5, 136.00; 6337.2, 134.00; 10225.2, 139.00; 
10282.5, 130.00; 10580.4, 150.00; 10674.6, 133.00; 10726.5, 135.00; 10763.7, 134.00; 10820.1, 
142.00; 10843.9, 142.00; 10936.6, 134.00; 10997.3, 133.00; 11040.8, 133.00 
(MeO-PEG-NH)10kDa-STZ: m/z 5240.9, Intens. 56.00; 5462.7, 68.00; 5550.5, 58.00; 5559.4, 72.00; 
5572.1, 58.00; 5598.9, 57.00; 5742.2, 60.00; 5840.9, 60.00; 5886.5, 56.00; 5970.0, 62.00; 6076.8, 
59.00; 6399.6, 55.00; 10116.8, 69.00; 10128.2, 58.00; 10142.5, 56.00; 10251.0, 64.00; 10253.3, 
56.00; 10268.4, 60.00; 10286.4, 57.00; 10302.2, 64.00; 10318.4, 55.00; 10337.7, 61.00; 10351.3, 
66.00; 10371.6, 55.00; 10408.4, 68.00; 10429.6, 60.00; 10473.6, 69.00; 10495.5, 64.00; 10514.7, 
74.00; 10530.6, 65.00; 10556.8, 56.00; 10574.5, 60.00; 10594.2, 88.00; 10619.9, 73.00; 10655.4, 
60.00; 10691.0, 82.00; 10710.3, 63.00; 10778.1, 71.00; 10794.8, 67.00; 10813.8, 75.00; 10843.2, 
62.00; 10856.9, 67.00; 10912.5, 63.00; 10963.2, 60.00; 11002.1, 60.00; 11059.1, 57.00; 11076.4, 
67.00; 11099.1, 57.00; 11140.1, 65.00; 11303.0; 66.00 
 
2.2.8. Cross reactivity of STZ and (MeO-PEG-NH)10kDa-STZ toward TST by AChE competitive 
enzyme-linked immunosorbent assay (ELISA) 
The competition between TST, STZ and (MeO-PEG-NH)10kDa-STZ and a TST-AChE conjugate (TST 
tracer) for a limited amount of TST antiserum was estimated by the commercial Testosterone ELISA-
Kit (Cayman Chemical, Ann Arbor, MI, USA). The ratio of the absorbance read at 412 nm of a 
particular sample (B) to that of the maximum TST tracer amount (B0) bound by the antibody in the 
absence of free analyte was calculated in duplicate for four different concentrations (500, 125, 31.25 
and 7.8125 pg/mL) of TST, STZ and (MeO-PEG-NH)10kDa-STZ, according to the manufacturer’s 
instructions available at the following URL: https://www.caymanchem.com/pdfs/582701.pdf (Table 
2). Cross reactivity is calculated by comparing the mid-point (50% B/B0) value of TST, STZ and 
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(MeO-PEG-NH)10kDa-STZ to the mid-point (50% B/B0) value of TST when each is measured in assay 
buffer using the following formula: 
%Cross recovery  
Molecules that possess similar epitopes to the primary analyte of interest (TST) can compete with the 
TST tracer for binding to the primary antibody (monoclonal anti-rabbit IgG that has been previously 
attached to the well from the company in the commercial kit). Cross reactivity by considering alone 
TST is considered as 100%. Substances that are superior to the analyte, in displacing the tracer, result 
in a cross reactivity that is greater than 100%. Whereas, substances that are inferior to the primary 
analyte, in displacing the tracer, result in a cross reactivity that is less than 100%. 
 
2.2.9 Cell culture and cytotoxicity of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ 
Saos-2 cells were cultured as already reported elsewhere (Cristiano et al., 2017). Briefly, cells were 
seeded in T75 cell culture flasks for growing adherent cells (Thermo Fisher Scientific, Italy), 
containing McCoy’s 5A medium supplemented with penicillin (100 UI/ml), streptomycin (100 
µg/ml), amphotericin B (250 µg/ml) and FBS (10%, v/v), at 37 °C in a humidified atmosphere of 5% 
CO2 (Guaire® TS Autoflow Codue Water-Jacketed Incubator). Medium was refreshed every 48 h. 
Cells reaching the 70% of confluence were splatted adding 2 mL of trypsin, then further amplified 
after being collected by centrifugation for 10 min. at 1000 RPM and RT (Eppendorf Centrifuge 
58100, Eppendorf, Hamburg, Germany). 
Cytotoxicity of (MeO-PEG-NH)10kDa-STZ, compared with free STZ and (MeO-PEG-NH2)10kDa, was 
evaluated by performing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay for up 80 h. The percentage of viable cells was indirectly determined by MTT dye reduction. 
Indeed, MTT is reduced by active mitochondria in living cells (Mosmann, 1983). MTT assay was 
performed according to the modified method firstly described by Sladowski et al. in 1993 (Sladowski 
et al., 1993). Briefly, 10×103 Saos-2 cells/0.2 mL of McCoy’s 5A supplemented medium were 
cultured in the 96-well plate (Thermo Fisher Scientific, Italy) for 24 h at 37 °C (Gao et al., 2019; 
Morsi et al., 2019). Subsequently, the culture medium was replaced with 0.2 mL of McCoy’s 5A 
supplemented medium containing 1, 10, 25 or 50 µM STZ and/or (MeO-PEG-NH)10kDa-STZ, which 
were solubilized in a minimal volume of DMSO, then in the same culture medium by fixing the 
number of equivalent weights of STZ. Cell culture medium (CCM), DMSO and (MeO-PEG-
NH2)10kDa were used as controls. After 1, 4, 20 or 80 h, 20 µL of MTT solution (5 mg of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide/mL of PBS) were added to each well and left 
under incubation for 3 h (De Rose et al., 2016). 200 µL of a solution of DMSO/ethanol (1:1, v/v) was 
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added to each well after discarding the supernatants. After a stirring of 20 min. at 230 RPM on the 
orbital shaker KS130 Control (IKA®-Werke GmbH & CO, Staufen imBreisgau, Germany), the 
absorbance (Abs) of dissolved MTT formazan crystals was read at 570 nm by using the xMark™ 
Microplate Absorbance Spectrophotometer (Bio-Rad, Hercules, CA, USA). The cell viability 
percentage was calculated by using the following equation: 
Cell viability (%) = (AbsT/AbsC) × 100 
where AbsT is the absorbance of the absorbance of cells that has undergone a treatment and AbsC is 
the absorbance of control (untreated) cells. Three different independent experiments were done in 
duplicate. 
 
3. Results and Discussion 
HPLC is a powerful analytical technique that is widely used for the measurement of PEGylated small 
drugs (Cheng et al., 2012). HPLC spectra of STZ and (MeO-PEG-NH)10kDa-STZ conjugate are 
shown in Figs 1A-B, respectively. As shown in Fig. 1B, RP-HPLC of (MeO-PEG-NH)10kDa-STZ 
conjugate (total run time of 45 min.) demonstrates the synthesis of a pure compound (purity grade ≥ 
99%), thus validating the process of purification used during the synthesis of product (see Section 
2.2.2.). Due to the physicochemical property of the attached PEG, a longer retention time for 
PEGylated STZ was expected, as previously reported for PEGylated peptides (Park and Na, 2016). 
In fact, STZ eluted as a single peak at about 15 min. (Fig. 1A, 15.0 min), whereas (MeO-PEG-
NH)10kDa-STZ conjugate postponed its elution time at about 28 min. (Fig. 1B, 27.6 min.). 
Besides increasing water solubility, PEGylation increases stability of drugs, minimizing their 
cleavage and therefore increasing their half-life (Veronese and Pasut, 2005; Conover et al., 2003). 
In order to mimic the pH, osmolarity, and ion concentrations of the human body fluids, the stability 
of PEGylated STZ (1 mg/mL) was evaluated in phosphate buffer (PB) solution, buffered at pH 7.4 
and 5.8, by performing quantitative RP-HPLC analyses (see Section 2.2.3.). PB at pH 7.4 simulates 
human blood and its normal pH value, which is tightly regulated between 7.35 and 7.45. On the other 
hand, PB at pH 5.8 is considered like fluids of acidic organelles, such as lysosomes, which have a pH 
value ranged between 3.5 and 6.0 (Casey et al., 2010). Lysosomes contain hydrolases that facilitate 
the decomposition of proteins, lipids, and polysaccharides. These enzymes are active in acidic 
conditions, requiring the organelle to maintain an optimal luminal pH between 4 and 5 (Pillay et al., 
2002). Prolonged STZ administration provokes an increase in the activities of these liver lysosomal 
hydrolases (Molano et al., 1999), thus showing their involvement in the drug degradation. 
Interestingly, RP-HPLC analyses have shown a very high stability of (MeO-PEG-NH)10kDa-STZ 
conjugate at both pH values throughout 80 h (Fig. 2). In particular, after 80 h the (MeO-PEG-
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NH)10kDa-STZ amounts found in the PB solution ranged between 69.83% (PB, pH 5.8) and 87.27% 
(PB, pH 7.4). Conversely, at the same time point, the amounts of STZ was ranged between 10.28% 
(PB, pH 5.8) and 11.67% (PB, pH 7.4) (Fig. 2). The solubility of STZ in the PEG conjugate increased 
up to approximately 260-269×103 times than bare STZ, as measured in mQ water (25 °C, 1 atm) 
(Table 3). These data agree with those previously obtained by Conover and co-authors, who 
demonstrated that different PEG40kDa-Amphotericin B conjugates showed less hydrolysis following 
24 h incubation in PB pH 7.4 and greater solubility in aqueous solutions than free PEG40kDa and 
Amphotericin B, as a result of PEGylation (Conover et al., 2003). These data could involve the 
reduction of drug administration frequency, thus enhancing both compliance and life quality of 
patients (Cheng et al., 2012; Veronese and Pasut, 2005). 
As it can be seen from ATR-FTIR spectra in Fig. 3, a broad and small IR signal in the range 3425-
3075 cm-1, belonging to the stretching frequency of a free alcohol (OH) group, can be assigned to OH 
group bonded to the C17 of STZ. As expected, this signal is not present in both (MeO-PEG-NH2)10kDa 
and (MeO-PEG-NH)10kDa-STZ compounds. Indeed, in (MeO-PEG-NH2)10kDa there are no OH groups. 
In addition, the nucleophilic substitution by 4-nitrophenyl chloroformate at the OH group bonded to 
the C17 of STZ allows the synthesis of 17-(4-nitrophenyl carbonate) STZ (Product 1, Scheme 1). This 
is why the signal of any OH group is not present in the spectrum of (MeO-PEG-NH)10kDa-STZ 
conjugate. All vibrational modes (3n-6 = 162 normal modes) of STZ, defining 60 stretching, 122 
bending, and 28 torsion internal coordinates, by including redundancies (Lemma et al., 2017), may 
be found in its relative IR spectrum (Fig. 3). It is much more difficult to pick out individual bonds in 
the region to the right-hand side of the diagram from about 1875 to 625 cm-1 (fingerprint region). 
Even though these complicated series of absorptions are due to all configurations of bending 
vibrations within all analyzed molecules, the characteristic signal of PEG in (MeO-PEG-NH2)10kDa 
and (MeO-PEG-NH)10kDa-STZ compounds is present in the resulting ATR-FTIR spectra (Dupeyrón 
et al., 2013). The synthesis of (MeO-PEG-NH)10kDa-STZ conjugate is confirmed by the stretching of 
carbamate CN bond falling at around 2025-1925 cm-1. 
The carbamate CN bond belonging to (MeO-PEG-NH)10kDa-STZ conjugate was also confirmed by 
performing the 1H-NMR characterization of the resulting synthetic product. Indeed, by comparing 
the chemical shift (δ) assignments for each proton signal belonging to STZ (see carbon numbering of 
STZ molecular structure reported in Fig. 4A) with those of (MeO-PEG-NH)10kDa-STZ (Fig. 4C), they 
are easily recognizable: (i) the range of chemical shifts belonging to hydrogens of (OCH2CH2)O- 
group (Fig. 4B-C; backbone peak, δ = 3.0-4.0 ppm,) (Dust et al., 1990); (ii) the chemical shift 
belonging to hydrogen of -NHCO- group (Fig. 4C; single peak, δ = 5.574) (Digilio et al., 2003). 
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C21H32N2O, C5H13NO2∙[C2H4O]225 and C27H43N3O4∙[C2H4O]225 are the theoretical empirical formulas 
of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ, respectively (Scheme 1). According 
to their empirical formula, specific percentage compositions for the chemical elements N, C, H, and 
O are expected. As shown in the Table 4, the elemental CHNS(O) analysis did not confirm the 
percentage compositions exactly such as predicted, especially for C5H13NO2∙[C2H4O]225 and 
C27H43N3O4∙[C2H4O]225. The results obtained fit better to C5H13NO2∙[C2H4O]248 and 
C27H43N3O4∙[C2H4O]248, i.e., for minimal formula including a greater number of C2H4O units. As 
usually it happens, the supplier could have produced a MeO-PEG-NH2 with a slightly higher MW 
close to 11000 Da than the declared one (10 kDa, Iris Biotech GmbH, Product code: PEG1151). 
Nevertheless, the difference between the theoretical percentage composition and that found 
experimentally (│Diff.│) about the chemical elements N, C, H and O never exceeded 0.5. The low 
values of │Diff.│, besides confirming the predicted empirical formulas, demonstrate also that the 
obtained products, especially about STZ and (MeO-PEG-NH)10kDa-STZ, maintained their structural 
double bonds, thus confirming their high stability. Since elemental CHNS(O) analysis is based on a 
combustion process, the percentage of O was calculated by subtracting to 100% the relative 
percentage of the chemical elements N, C, H and S. The latter chemical element was quantified in 
order to evaluate possible reaction impurities. It is worth noting that this very low deviation means 
having obtained very pure reaction products. In fact, the percentages of S never exceeded 0.09%, 
proving that the nitrogen and sulfur were under the limit of quantification (LOQ) of their respective 
calibration curves. 
MWs of (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ were also investigated by MALDI-
TOF/TOF MS. As shown in Fig. 5, (MeO-PEG-NH2)10kDa gives rise to a characteristic MS 
fragmentation, further confirmed in the MS fragmentation of (MeO-PEG-NH)10kDa-STZ. Indeed, due 
to its characteristic fragmentation pattern allowing accurate and reproducible tuning, PEG is often 
used as an internal calibration compound in MS analyses. In the spectrum of (MeO-PEG-NH2)10kDa 
(Fig. 5A), the heaviest ion, which is the product ion m/z 11040.8, is likely to be the molecular ion 
M+. Even though the difference in MW found here compared to what declared by the supplier is not 
to be considered significant for this type of polymers (ΔMW = 1040.8 Da, +10.4% than declared by 
supplier), again, this value did not match its nominal MW (10 kDa). Conversely, it almost fits 
perfectly with a compound having a minimal formula C5H13NO2∙[C2H4O]248, therefore a MW of 
11044.2 Da (ΔMW = 3.4 Da). M+ of (MeO-PEG-NH)10kDa-STZ is found at m/z 11303.0 instead at 
m/z 10385.5. Once again, this value of m/z found in the spectrum fits perfectly with a value of m/z 
11398.7, i.e., for a M+ ensuing from the compound C5H13NO2∙[C2H4O]248. Peaks found at lower m/z 
can be assigned to product ions resulting from fragmentation of (MeO-PEG-NH2)10kDa, either alone 
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or if conjugated with STZ to form (MeO-PEG-NH)10kDa-STZ (see Section 2.2.7.). This data fits with 
the finding of Onigbinde et al. (2013), who found that methane positive-ion mode chemical ionization 
of PEGs gives rise to spectra in which the peaks consist mostly of MH+, (C2H4O)nH+, 
(H(OC2H4)nOH)H2+, and CH3(OC2H4)n+ ions and small amount of C2H5OC2H4+ ions (Onigbinde et 
al., 2013). 
Once the chemical nature of the compound (MeO-PEG-NH)10kDa-STZ has been stated, its 
competitiveness against TST was evaluated. In particular, cross reactivity of different concentrations 
(500, 125, 31.25 and 7.8125 pg/mL) of TST, STZ or (MeO-PEG-NH)10kDa-STZ against the same 
concentrations of TST was evaluated by performing AChE competitive ELISA (see Section 2.2.8.). 
STZ or (MeO-PEG-NH)10kDa-STZ were less able than TST to displace the AChE-linked TST bound 
to TST antiserum (Fig. 6). STZ has low affinity for binding the AR too. However, it strongly activates 
AR-mediated signaling (Feldkoren, and Andersson, 2005). Surprisingly, cross reactivity of STZ or 
(MeO-PEG-NH)10kDa-STZ against TST increased with decreasing concentrations, (MeO-PEG-
NH)10kDa-STZ more than STZ (p<0.05). Differences in physicochemical properties (e.g., water 
solubility, specificity of immunoassay for the principal ligand) between TST and STZ, either alone 
or as (MeO-PEG-NH)10kDa-STZ, could explain this phenomenon (Miller and Valdes, 1991). 
Nevertheless, the fact that (MeO-PEG-NH)10kDa-STZ competes against biological TST at lower 
concentrations, with a cross reactivity close to 100%, makes it very useful as a drug. 
Fig. 7A-D shows the cytotoxicity time-courses (for up 80 h) of increasing concentrations (1, 10, 25 
or 50 µM) of STZ and/or (MeO-PEG-NH)10kDa-STZ that have been evaluated using the MTT assay 
on human osteosarcoma Saos-2 cells, which express AR and are responsive to STZ (Ghiacci et al., 
2018; Orwoll et al., 1991). STZ decreased the cell viability of both glial and neuronal primary cortical 
cells up to 24 h of treatment and in the range of concentrations from 10 to 100 µM. Intermediate 
concentrations of STZ (10 and 30 µM), administered every 24 h for three consecutive days, resulted 
still nontoxic to cells, while higher concentrations (100 µM) reduced cell viability by about 50% 
(Zelleroth et al., 2019). Conversely, STZ affects the cell viability of Saos-2 cells, by inducing a cell 
loss of 17% already after 4 h of treatment, at a concentration 1 µM (STZ vs. CCM, p<0.05; Fig. 7A). 
This cell loss reached 96% after 80 h of treatment, at a concentration 50 µM (STZ vs. CCM, p<0.05; 
Fig. 7D). Interestingly, high values of cell vitality were obtained upon treatment with (MeO-PEG-
NH)10kDa-STZ, due to the presence of (MeO-PEG-NH2)10kDa (Fig. 7A-D). In fact, compared to STZ-
treated cells, cells treated with (MeO-PEG-NH)10kDa-STZ showed cell viability values in the range 
from +3% (1 µM at 20 h, p<0.05; Fig. 7A) to +41% (50 µM at 4 h, p<0.05; Fig. 7D). PEGs have 
generally been reported to be nontoxic to cells (Kaul et al., 2002). Indeed, (MeO-PEG-NH2)10kDa, 
when compared to the alone CCM, showed the least toxic tested for cells if compared to other 
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formulations, thus decreasing cell viability by 39% after 80 h of treatment at a concentration of 50 
µM (p<0.05; Fig. 7D). This lack of toxicity may depend on that generally PEGs do not bind to the 
proteins of cells (Lee et al., 1995). Furthermore, PEGylation of inorganic nanoparticles, like 
nanorods, lack significantly their cytotoxicity in vitro on human endothelial cells (Li et al., 2019). To 
demonstrate that it was the STZ and not the (MeO-PEG-NH2)10kDa to be cytotoxic, intermediate cell 
viability values between STZ-treated and (MeO-PEG-NH)10kDa-STZ-treated cells, closer to the first 
ones, were observed when the Saos-2 cells underwent the treatment (MeO-PEG-NH)10kDa-STZ + STZ 
(Fig. 7A-D). DMSO, which has been used at the minimum volume to dissolve STZ and have the 
stock solution for in vitro experiments (see Section 2.2.9), was nontoxic to cells. DMSO was toxic 
for Saos-2 cells after 20 h of treatment at a concentration of 50 µM, when a decrease of 38% in cell 
viability was obtained compared to cells treated with CCM alone (p<0.05; Fig. 7D).  
 
4. Conclusions 
As confirmed by RP-HPLC, ATR-FTIR, 1H-NMR, elemental CHNS(O) and MALDI-TOF/TOF MS 
analyses, a (MeO-PEG-NH)10kDa-STZ conjugate was synthesized with a high degree of purity. 
PEGylation increased stability and water solubility of STZ, therefore its bioavailability and efficacy 
(Cheng et al., 2012; Veronese and Pasut, 2005; Conover et al., 2003). RP-HPLC analysis has 
shown a very high stability of (MeO-PEG-NH)10kDa-STZ conjugate in PB, buffered either at pH 5.8 
and at 7.4, for up 80 h at 37 °C. In addition, higher drug bioavailability and efficacy can decrease the 
frequency of administration and thus increasing the  compliance and life quality of patients (Cheng 
et al., 2012; Veronese and Pasut, 2005). AChE competitive ELISA showed that this compound 
competes against biological TST especially at lower concentrations. Saos-2 cell viability data 
demonstrated that PEGylation opposed the cytotoxicity of STZ alone, with (MeO-PEG-NH)10kDa-
STZ inducing higher cell viability values than STZ, especially at higher drug concentrations. 
Conversely, resulting data showed that (MeO-PEG-NH)10kDa-STZ could be taken into consideration 
as a promising and reliable drug to be used in clinical conditions requiring TST. 
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Graphical Abstract caption 
Stanozolol (STZ) conjugated with α-methoxy-ω-amino polyethylene glycol with nominal molecular 
weight (MW) of 10,000 Da, (MeO-PEG-NH)10kDa-STZ, was synthesized to maintain the native 
therapeutic activity of drugs and have a water soluble and stable compound, showing the same 
therapeutic property of STZ. The resulting PEGylated STZ presents a promising and reliable drug to 
treat testosterone deficiencies. 
 
Scheme captions 
Synthesis of (MeO-PEG-NH)10kDa-STZ conjugate. Product 1 = 17-(4-nitrophenyl carbonate) STZ; 
Product 2 = (MeO-PEG-NH)10kDa-STZ; TEA = triethylamine. 
 
Figure captions 
Figure 1. Representative RP-HPLC chromatograms of STZ (A) and (MeO-PEG-NH)10kDa-STZ (B) 
compounds (100 µg/mL, wavelength of UV/VIS HPLC detector set at 230 nm), by plotting the 
absorbance (in arbitrary units, AU) vs. elution time (in min.). 
Figure 2. Stability of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ conjugate in PB 
solution, buffered at pH 5.8 and 7.4, for up 80 h at 37 °C. For each time point, the amount of intact 
compound that remained in solution was determined by performing quantitative RP-HPLC analysis 
(wavelength of UV/VIS HPLC detector set at 230 nm). Data represent the mean (± SE) of two 
independent experiments. * = significant value vs. the value reported at the time point 0 h (p<0.05); 
× = significant value with respect to the same compound in PB solution buffered at pH 5.8 (p<0.05). 
Figure 3. Representative ATR-FTIR spectra (4000-625 cm-1) of STZ (spectrum in black), (MeO-
PEG-NH2)10kDa (spectrum in red) and (MeO-PEG-NH)10kDa-STZ (spectrum in green) compounds. 
Grey band on left side indicates the absorption range associated with alcohol bond (OH) stretching, 
whereas grey band on right side indicates that of carbamate bond (CN) stretching. 
Figure 4. Representative 1H-NMR spectra of STZ (A), (MeO-PEG-NH2)10kDa (B) and (MeO-PEG-
NH)10kDa-STZ (B) compounds (for detailed information on the analysis see Section 2.2.5.). 
Figure 5. Representative positive-ion MALDI-TOF/TOF MS spectra of (MeO-PEG-NH2)10kDa (A) 
and (MeO-PEG-NH)10kDa-STZ (B) compounds in the m/z range 5000-19000 (for detailed information 
on the analysis see Section 2.2.7.) 
Figure 6. Cross reactivity (%) of different concentrations of TST, STZ and (MeO-PEG-NH)10kDa-
STZ toward TST (primary analyte of interest) calculated by comparing the mid-point (50%) B/B0 
value of TST, STZ or (MeO-PEG-NH)10kDa-STZ to the mid-point (50%) B/B0 value of TST when 
each was measured at 412 nm (see Section 2.2.8.). For each concentration point, the cross reactivity 
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by considering alone TST was considered as 100%. Data represent the mean (± SE) of two 
independent experiments. * = significant value vs. TST (p<0.05); × = significant value vs. (MeO-
PEG-NH)10kDa-STZ (p<0.05). 
Figure 7. Cytotoxicity of 1 µM (A), 10 µM (B), 25 µM (C) and 50 µM (D) STZ and/or (MeO-PEG-
NH)10kDa-STZ evaluated for up 80 h by performing the MTT assay on human osteosarcoma Saos-2 
cells. Cell culture medium (CCM), dimethyl sulfoxide (DMSO) and (MeO-PEG-NH2)10kDa were used 
as controls. Data represent the mean (± SE) of three independent experiments as duplicate. * = 
significant value vs. CCM (p<0.05); × = significant value vs. (MeO-PEG-NH2)10kDa (p<0.05); ○ = 
significant value vs. STZ (p<0.05). 
 
Table captions 
Table 1. Integration limits set to perform elemental CHNS(O) analysis. 
Table 2. %B/B0 values of TST, STZ and (MeO-PEG-NH)10kDa-STZ as found by performing AChE 
competitive ELISA. 
Table 3. Solubility of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ in milliQ water (25 
°C, 1 atm). 
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Element Min Max 
N 314 29766 
C 649 54507 
H 22 19023 
S 109 10843 
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Table 3. Solubility of STZ, (MeO-PEG-NH2)10kDa and (MeO-PEG-NH)10kDa-STZ in milliQ water 












Difference in solubility with respect to 
that of STZ (Folds ×103) 
- 289-301 260-269 
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